/
LIPO
$0.06-$0.03 (-35.56%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.02 – $1.00
4% from low
Exchange
OTC Link
CS
Borrow rate
43.71%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-37.62
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue | $694.7K | $961.7K | $259.3K | $184.2K | $449.6K | $536.4K |
| Cost of revenue | $682.9K | $976.0K | $1.5M | $2.5M | $3.0M | $3.6M |
| Gross profit | $11.9K | −$14.3K | −$1.2M | −$2.4M | −$2.6M | −$3.1M |
| Gross margin | 1.7% | -1.5% | -461.7% | -1283.4% | -575.9% | -573.7% |
| R&D | $682.9K | $976.0K | $1.5M | $2.5M | $3.0M | $3.6M |
| Operating income | −$53.8K | −$56.9K | −$1.9M | −$2.6M | −$4.7M | −$5.1M |
| EBITDA | $0 | −$53.7K | −$1.9M | −$2.6M | −$4.6M | −$5.0M |
| Net income | −$61.8K | −$61.7K | −$1.9M | −$2.6M | −$4.6M | −$5.0M |
| Net margin | -8.9% | -6.4% | -719.3% | -1410.6% | -1027.3% | -935.2% |
| EPS (diluted) | -0.24 | -0.23 | -4.38 | -5.12 | -6.16 | -4.79 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $583664 | $-17.42 | $-17.42–$-17.42 | 1 |
| 2027 | $608860 | $-2.18 | $-2.18–$-2.18 | 1 |
| 2028 | $26M | $0.40 | $0.40–$0.40 | 1 |
| 2029 | $47M | $2.53 | $2.53–$2.53 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
LIPELLA PHARMS INC
LIPELLA PHARMS INC
Held by traders on TradeandTell
No one on the platform currently holds LIPO.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in LIPO as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-11-08 | 1-for-8reverse |
Recent trades on TradeandTell
No one on the platform has traded LIPO yet.
